SCHEMBL209942

SCHEMBL209942

O[C@H]1COC[C@@H]1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13660720 1.00
SCHEMBL209943 1.00
SCHEMBL29016131 1.00 THRB (0.41)
SCHEMBL196429 1.00
SCHEMBL209944 1.00
SCHEMBL23284422 1.00
Hydrochloric Acid SCHEMBL28195227 0.96
SCHEMBL4580880 0.87 FUCA1 (0.39)
SCHEMBL846334 0.87 FUCA1 (0.39)
Bicarbonate SCHEMBL10392138 0.86 THRB (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4211119-B1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2026-05-13 EP disclosed
EP-4355748-B1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2026-05-13 EP disclosed
US-12570640-B2 2-aminoquinazolines as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-03-10 US disclosed
US-12540131-B2 N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof MERCK SHARP & DOHME LLC (US) 2026-02-03 US disclosed
US-20240383901-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-11-21 US disclosed
WO-2024135510-A1 MULTILAYER BODY FOR LIQUID PACKAGING MATERIALS, AND PACKAGING MATERIAL DIC株式会社 2024-06-27 WO disclosed
EP-4355748-A1 SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2024-04-24 EP disclosed
CN-117881681-A Substituted pyrrolo [2,3-d ] pyrimidines, their preparation and their therapeutic use 赛诺菲 2024-04-12 CN disclosed
US-20230303540-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF MERCK SHARP & DOHME LLC (US) 2023-09-28 US disclosed
EP-4211119-A1 2-AMINOQUINAZOLINES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Merck Sharp & Dohme LLC (US) 2023-07-19 EP disclosed
US-5916975-A Process for epoxidising prochiral olefins and a catalyst therefor and intermediates for making the catalyst SMITHKLINE BEECHAM P.L.C. (GB) 1999-06-29 US disclosed
US-5912247-A BLOOD FLOW INHIBITION; SIDE EFFECT REDUCTION KANEBO, LTD. (JP) 1999-06-15 US disclosed
US-5616750-A Compounds and process SMITHKLINE BEECHAM PLC (GB) 1997-04-01 US disclosed
EP-0743308-A2 Quinazoline compound and anti-tumor agent containing said compound as an active ingredient KANEBO, LTD. (JP) 1996-11-20 EP disclosed
EP-0741731-A1 PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST SMITHKLINE BEECHAM PLC (GB) 1996-11-13 EP disclosed
EP-0655950-B1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY SMITHKLINE BEECHAM PLC (GB) 1996-10-23 EP disclosed
EP-0667245-A1 Recording sheets containing alcohols and saccharides XEROX CORPORATION (US) 1995-08-16 EP disclosed
WO-1995021172-A1 PROCESS FOR EPOXIDISING PROCHIRAL OLEFINS AND A CATALYST THEREFOR AND INTERMEDIATES FOR MAKING THE CATALYST SMITHKLINE BEECHAM P.L.C. (GB) 1995-08-10 WO disclosed
EP-0655950-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY. SMITHKLINE BEECHAM PLC (GB) 1995-06-07 EP disclosed
WO-1994003271-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY SMITHKLINE BEECHAM PLC (GB) 1994-02-17 WO disclosed